Advertisement

Can antineutrophil cytoplasmic antibody positivity at diagnosis predict the poor outcomes of Sjögren’s syndrome?

  • Soo Bin Lee
  • Hyeok Choi
  • Minyoung Kevin Kim
  • Seung Min Jung
  • Jason Jungsik Song
  • Yong-Beom Park
  • Sang-Won LeeEmail author
Observational Research

Abstract

We investigated the clinical implication of ANCA positivity at diagnosis on the poor outcomes in patients with Sjögren’s syndrome. The medical records of 606 Korean patients with Sjögren’s syndrome were retrospectively reviewed. The results of perinuclear (P)-ANCA, myeloperoxidase (MPO)-ANCA, cytoplasmic (C)-ANCA, and proteinase 3 (PR3)-ANCA were collected and the frequencies of all-cause mortality, interstitial lung disease (ILD), end-stage renal disease (ESRD), and lymphoma were assessed as the poor outcomes of Sjögren’s syndrome. Comparison of the cumulative patient survivals between the two groups was analysed by the Kaplan–Meier survival analysis. Of the 606 patients, ANCA was detected in 10.2% of Sjögren’s syndrome patients without AAV. Twenty-one patients (3.5%) died, 99 patients (16.3%) suffered from ILD, and 8 patients had ESRD. Lymphoma occurred in 5 patients (0.8%) during 37.5 months. Sjögren’s syndrome patients with ANCA positivity exhibited a lower cumulative ILD-free survival rate than those with ANCA negativity (P = 0.001). Sjögren’s syndrome patients with P-ANCA positivity and those with MPO-ANCA (or P-ANCA) positivity showed a lower cumulative ILD-free survival rate than those without (P = 0.012 and P < 0.001). Also, Sjögren’s syndrome patients with P-ANCA positivity exhibited a lower cumulative ESRD-free survival rate than those without (P = 0.043). ANCA positivity was associated with neither all-cause mortality nor lymphoma in Sjögren’s syndrome patients. ANCA positivity and MPO-ANCA (or P-ANCA) positivity at diagnosis was associated with the development of ILD during follow-up in patients with Sjögren’s syndrome.

Keywords

Antineutrophil cytoplasmic antibody Sjögren’s syndrome Interstitial lung disease Predictor 

Notes

Author contributions

All authors contributed to conception and design, or acquisition of data, or analysis and interpretation of data, and participated in drafting the manuscript or revising it critically for important intellectual content. Also, all authors gave final approval of the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2017R1D1A1B03029050) and a Grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (HI14C1324).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was approved by the Institutional Review Board (IRB) of Severance Hospital (4-2017-0673).

Informed consent

The patients’ written informed consent was waived by the approving IRB, as this was a retrospective study.

Supplementary material

296_2019_4476_MOESM1_ESM.sav (25 kb)
Supplementary material 1 (SAV 25 kb)
296_2019_4476_MOESM2_ESM.docx (17 kb)
Supplementary material 2 (DOCX 16 kb)

References

  1. 1.
    Brito-Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, Sivils K, Theander E, Tzioufas A, Ramos-Casals M (2016) Sjögren syndrome. Nat Rev Dis Primers 2:16047.  https://doi.org/10.1038/nrdp.2016.47 CrossRefPubMedGoogle Scholar
  2. 2.
    Fayyaz A, Kurien BT, Scofield RH (2016) Autoantibodies in Sjögren’s Syndrome. Rheum Dis Clin N Am 42(3):419–434.  https://doi.org/10.1016/j.rdc.2016.03.002 CrossRefGoogle Scholar
  3. 3.
    Rischmueller M, Tieu J, Lester S (2016) Primary Sjögren’s syndrome. Best Pract Res Clin Rheumatol 30(1):189–220.  https://doi.org/10.1016/j.berh.2016.04.003 CrossRefPubMedGoogle Scholar
  4. 4.
    Csernok E, Moosig F (2014) Current and emerging techniques for ANCA detection in vasculitis. Nat Rev Rheumatol 10(8):494–501.  https://doi.org/10.1038/nrrheum.2014.78 CrossRefPubMedGoogle Scholar
  5. 5.
    Bossuyt X, Cohen Tervaert JW, Arimura Y, Blockmans D, Flores-Suárez LF, Guillevin L, Hellmich B, Jayne D, Jennette JC, Kallenberg CGM, Moiseev S, Novikov P, Radice A, Savige JA, Sinico RA, Specks U, van Paassen P, Zhao MH, Rasmussen N, Damoiseaux J, Csernok E (2017) Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 13(11):683–692.  https://doi.org/10.1038/nrrheum.2017.140 CrossRefPubMedGoogle Scholar
  6. 6.
    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65(1):1–11.  https://doi.org/10.1002/art.37715 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66(2):222–227.  https://doi.org/10.1136/ard.2006.054593 CrossRefPubMedGoogle Scholar
  8. 8.
    Lee IH, Kim SK, Kim MK (2016) Dual anti-neutrophil cytoplasmic antibody-related pauci-immune crescentic glomerulonephritis in a patient with Sjögren’s syndrome. Rheumatol Int 36(9):1327–1334.  https://doi.org/10.1007/s00296-016-3520-5 CrossRefPubMedGoogle Scholar
  9. 9.
    Morimoto C, Fujigaki Y, Tamura Y, Ota T, Shibata S, Asako K, Kikuchi H, Kono H, Kondo F, Yamaguchi Y, Uchida S (2018) Emergence of smoldering ANCA-associated glomerulonephritis during the clinical course of mixed connective tissue disease and Sjögren’s syndrome. Intern Med 57(12):1757–1762.  https://doi.org/10.2169/internalmedicine.9844-17 CrossRefPubMedGoogle Scholar
  10. 10.
    Hsu CW, Su YJ, Chang WN, Tsai NW, Chiu WC, Cheng BC, Su CM, Huang CR, Chang YT, Lu CH (2014) The association between serological biomarkers and primary Sjogren’s syndrome associated with peripheral polyneuropathy. Biomed Res Int 2014:902492.  https://doi.org/10.1155/2014/902492 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Guellec D, Cornec-Le-Gall E, Groh M, Hachulla E, Karras A, Charles P, Dunogué B, Abad S, Alvarez F, Gérard F, Devauchelle-Pensec V, Pers JO, Puéchal X, Guillevin L, Saraux A, Cornec D, CRI (Club Rhumatismes et Inflammation) and the French Vasculitis Study Group (2015) ANCA-associated vasculitis in patients with primary Sjögren’s syndrome: detailed analysis of seven new cases and systematic literature review. Autoimmun Rev 14(8):742–750.  https://doi.org/10.1016/j.autrev.2015.04.009 CrossRefPubMedGoogle Scholar
  12. 12.
    Specks U, Wiegert EM, Homburger HA (1997) Human mast cells expressing recombinant proteinase 3 (PR3) as substrate for clinical testing for anti-neutrophil cytoplasmic antibodies (ANCA). Clin Exp Immunol 109(2):286–295.  https://doi.org/10.1046/j.1365-2249.1997.4561353.x CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Noel N, André C, Bengoufa D, Dehoulle C, Mahler M, Limal N, Godeau B, Hüe S (2013) Performance evaluation of three assays for the detection of PR3-ANCA in granulomatosis with polyangiitis in daily practice. Autoimmun Rev 12(12):1118–1122.  https://doi.org/10.1016/j.autrev.2013.06.009 CrossRefPubMedGoogle Scholar
  14. 14.
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren’s Syndrome (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis 61(6):554–558.  https://doi.org/10.1136/ard.61.6.554 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, Mariette X, International Sjögren’s Syndrome Criteria Working Group (2017) 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren’s Syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 69(1):35–45.  https://doi.org/10.1002/art.39859 CrossRefPubMedGoogle Scholar
  16. 16.
    Vassar M, Holzmann M (2013) The retrospective chart review: important methodological considerations. J Educ Eval Health Prof 10:12.  https://doi.org/10.3352/jeehp.2013.10.12 CrossRefPubMedGoogle Scholar
  17. 17.
    McAdoo SP, Tanna A, Hrušková Z, Holm L, Weiner M, Arulkumaran N, Kang A, Satrapová V, Levy J, Ohlsson S, Tesar V, Segelmark M, Pusey CD (2017) Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int 92(3):693–702.  https://doi.org/10.1016/j.kint.2017.03.014 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Salmela A, Törnroth T, Poussa T, Ekstrand A (2018) Prognostic factors for survival and relapse in ANCA-associated vasculitis with renal involvement: a clinical long-term follow-up study. Int J Nephrol 2018:6369814.  https://doi.org/10.1155/2018/6369814 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Rhee RL, Hogan SL, Poulton CJ, McGregor JA, Landis JR, Falk RJ, Merkel PA (2016) Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease. Arthritis Rheumatol 68(7):1711–1720.  https://doi.org/10.1002/art.39614 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Alba MA, Flores-Suárez LF, Henderson AG, Xiao H, Hu P, Nachman PH, Falk RJ, Charles Jennette J (2017) Interstital lung disease in ANCA vasculitis. Autoimmun Rev 16(7):722–729.  https://doi.org/10.1016/j.autrev.2017.05.008 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Millet A, Pederzoli-Ribeil M, Guillevin L, Witko-Sarsat V, Mouthon L (2013) Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? Ann Rheum Dis 72(8):1273–1279.  https://doi.org/10.1136/annrheumdis-2013-203255 CrossRefPubMedGoogle Scholar
  22. 22.
    Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH (2006) Interstitial lung disease in primary Sjögren syndrome. Chest 130(5):1489–1495.  https://doi.org/10.1378/chest.130.5.1489 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of MedicineYonsei University College of MedicineSeoulRepublic of Korea
  2. 2.Division of Rheumatology, Department of Internal MedicineYonsei University College of MedicineSeoulRepublic of Korea
  3. 3.Institute for Immunology and Immunological DiseasesYonsei University College of MedicineSeoulRepublic of Korea

Personalised recommendations